The PROTAC market is experiencing rapid growth, driven by rising interest in targeted protein degradation as a next-generation therapeutic approach. Expanding oncology pipelines with drugs in clinical ...
With over 10 years’ experience writing about consumer affairs, Sarah leads on energy content at Which?, helping customers navigate the market and exposing poor practice. If you haven't had a smart ...
(UroToday.com) The 2025 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Shun Zhang discussing a phase 1 study of QLH12016, an androgen receptor PROTAC degrader in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results